产品
编 号：F742970
产品类型
规格
价格
是否有货
结构图
CAS No: 1188275-92-4
产品详情
生物活性：
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.
体内研究：
Narnatumab (2-60 mg/kg; i.p. every 3 days) 在无胸腺小鼠的非小细胞肺癌 (NSCLC) 和膀胱癌模型中显示出抗肿瘤活性。Narnatumab 在小鼠体内的终末半衰期为 5.2 d，在约 140 μg/mL 的稳态血浆谷水平下实现抗肿瘤作用。Animal Model:Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells
Dosage:2, 20, 60 mg/kg
Administration:I.p. every 3 days for 36 and 18 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
Narnatumab (100 nM; 24 h) 抑制 MSP 诱导的人肺癌和乳腺癌细胞系迁移。Narnatumab 抑制 MSP 诱导的胰腺癌细胞有丝分裂反应。Narnatumab (0.01-100 nM; 预处理 1 h) 在表达 RON 的肿瘤细胞和转染 RON 的细胞系中阻断配体诱导的受体磷酸化和下游信号分子磷酸化。
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.
体内研究：
Narnatumab (2-60 mg/kg; i.p. every 3 days) 在无胸腺小鼠的非小细胞肺癌 (NSCLC) 和膀胱癌模型中显示出抗肿瘤活性。Narnatumab 在小鼠体内的终末半衰期为 5.2 d，在约 140 μg/mL 的稳态血浆谷水平下实现抗肿瘤作用。Animal Model:Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells
Dosage:2, 20, 60 mg/kg
Administration:I.p. every 3 days for 36 and 18 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
Narnatumab (100 nM; 24 h) 抑制 MSP 诱导的人肺癌和乳腺癌细胞系迁移。Narnatumab 抑制 MSP 诱导的胰腺癌细胞有丝分裂反应。Narnatumab (0.01-100 nM; 预处理 1 h) 在表达 RON 的肿瘤细胞和转染 RON 的细胞系中阻断配体诱导的受体磷酸化和下游信号分子磷酸化。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备